| Identification | Back Directory | [Name]
319H6 | [CAS]
924537-98-4 | [Synonyms]
319H6
BT 13 NEW
BT-13
(RET agonist BT13)
Benzenesulfonamide, N,N-diethyl-3-[4-[4-fluoro-2-(trifluoromethyl)benzoyl]-1-piperazinyl]-4-methoxy- | [Molecular Formula]
C23H27F4N3O4S | [MOL File]
924537-98-4.mol | [Molecular Weight]
517.54 |
| Chemical Properties | Back Directory | [Boiling point ]
637.0±65.0 °C(Predicted) | [density ]
1.326±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 25 mg/mL (48.31 mM) | [form ]
Solid | [pka]
0.42±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
BT-13 is a potent, selective agonist of the glial cell-derived neurotrophic factor (GDNF) receptor RET (acts independently of GDNF ligands), promotes sensory neuron neurite outgrowth in vitro, and alleviates neuropathy in rats happened. | [in vitro]
BT-13 stimulates phosphorylation of RET, as well as RET-dependent intracellular signaling, but activated neither NGF receptor TrkA nor BDNF receptor TrkB nor intracellular signaling in the absence of RET. < b> | [in vivo]
BT-13 (20 and 25mg/kg in rats induced by ligation of left L5 and L6 spinal nerves) has a slight antinociceptive/antihyperalgesic effect and protected DRG neurons in rats with surgery-induced neuropathy. | Animal Model: | Rats induced by ligation of left L5 and L6 spinal nerves. | | Dosage: | 5-25 mg/kg, dissolved in sesame oil containing 5% DMSO. | | Administration: | Subcutaneous injections on post-surgical days 1, 3, 5, 8, 10, and 12. | | Result: | 20 and 25mg/kg decreased mechanical hypersensitivity and normalized expression of sensory neuron markers in dorsal root ganglia. | | [target]
|
|
|